市場調查報告書
商品編碼
1245183
全球在線藥房市場 - 按產品(OTC 產品、處方藥)、地區、增長潛力、競爭市場份額、全球預測,2023-2032 年E-pharmacy Market - By Product (OTC Products, Prescription Medicine), By Region, Growth Potential, Competitive Market Share & Global Forecast, 2023 - 2032 |
到 2032 年,全球在線藥店市場預計將呈現積極跡象,因為處方藥可以通過在線渠道以折扣價購買。
醫生處方藥的合法化也將對收入產生積極影響。 此外,越來越多的初創企業正在加劇市場領導者之間的競爭。
最重要的是,電子藥店使購買藥品變得更加容易,特別是對於遠離傳統藥店的人、殘疾人、老年人和工作強度大的人來說。 航運也比旅行更實惠,省錢。 在線藥店提供的另一個好處是節省時間。 在線藥店配送以及客戶隱私和機密性可以進一步加速市場動態。 根據一項調查,96% 的美國成年人表示科技讓他們更容易開處方和管理藥物。
市場領先的供應商正在通過併購、合作夥伴關係、研發投資和新產品發布等戰略努力來提高他們在行業中的競爭力。 例如,印度電子商務巨頭 Flipkart 正在洽談收購總部位於班加羅爾的在線藥店初創公司 Pharmallama。 此次收購將使 Flipkart 能夠在印度推出 Flipkart Health+。
總體而言,在線藥店行業在產品和區域方面存在細分。
按產品劃分,倫理藥品領域預計在預計期間將顯著增長。 產品可用性是促進該細分市場增長的主要因素。 此外,促進處方藥銷售的政策改進將在未來加速分部收益。
例如,在 2023 年,亞馬遜將推出一項新的處方藥計劃,以固定費用為訂閱者提供所需的藥物。 最新舉措是該集團試圖將科技公司推向醫療保健領域,以吸引顧客遠離藥店零售商。
按地區劃分,2022 年亞太在線藥店行業的價值將超過 190 億美元。 初創企業的增加和主要參與者之間的新興競爭將推動市場滲透到印度、中國和日本等新興經濟體。 毋庸置疑,折扣和獎勵等產品優勢將在預計期間推動市場擴張。 此外,每個國家增加對醫療基礎設施發展的投資將對該地區的增長產生積極影響。
E-pharmacy Market is anticipated to showcase a positive trajectory through 2032, owing to the increasing availability of prescription drugs on online channels at discounted prices. In addition, the legalization of physician-prescribed drugs will also positively influence revenue generation. Additionally, the rising number of startups has resulted in intense competition among market leaders.
Besides, e-pharmacies have made buying drugs easy, especially for people who live far from a traditional pharmacy, disabled people, the elderly, and those who work very intensively. The shipping cost is also more affordable than traveling, saving money. Another advantage offered by e-pharmacy is timesaving. Delivery through e-pharmacies and customer privacy and confidentiality can further accelerate the market dynamics. As per a study, 96% of American adults claimed that technology has made filling prescriptions and managing medications easier for them.
Key providers in the market are engaging in strategic initiatives such as mergers and acquisitions, partnerships, R&D investments, and new product launches to gain a competitive edge in the industry. For instance, Flipkart, one of the leading Indian e-commerce giants, is in advanced talks to acquire Pharmallama, a Bengaluru-based online pharmacy startup. The acquisition has enabled Flipkart to expand its e-pharmacy offering, Flipkart Health+, across the Indian subcontinent.
Overall, the e-pharmacy industry is segmented in terms of product and region.
Based on the product, the prescription medicine segment is slated to grow considerably during the estimated timeframe. Wide and easy product availability will be a major factor contributing to segment growth. Besides, improving policies to enable the sale of prescription drugs will accelerate the segment revenue in the future.
For instance, Amazon in 2023, launched a new prescription drug program offering its subscribers with medications as per their requirement for a flat fee. The latest move is the conglomerate's bid to attract customers away from retail drug stores as tech players enter the healthcare sector.
Regionally, the Asia Pacific e-pharmacy industry was valued at over USD 19 billion in 2022. An increasing number of startups coupled with budding competition among the key players in the region would prompt market penetration across developing economies including India, China, Japan, and others. Not to mention, product benefits such as discounts and offers will boost expansion during the estimated timeframe. Furthermore, the increasing investment in developing healthcare infrastructure in various countries will positively influence regional growth.